Merck & Co., Inc. is 167.8x more valuable than Nurix Therapeutics, Inc. by market capitalization ($294.03 B vs $1.75 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NRIX | MRK |
|---|---|---|
| Market cap | $1.75 B | $294.03 B |
| US-listed rank | #2211 | #45 |
| Revenue (latest FY) | $83.98M | $65.01B |
| Net income (latest FY) | -$264.46M | $18.25B |
| Net margin | -314.9% | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 511 | 996 |
Merck & Co., Inc. is 167.8x more valuable than Nurix Therapeutics, Inc. by market capitalization ($294.03 B vs $1.75 B).
In their latest fiscal years, Nurix Therapeutics, Inc. reported $83.98M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Nurix Therapeutics, Inc. and Merck & Co., Inc., or browse the full rankings.